奥赛康(002755.SZ)：子公司注射用德拉沙星葡甲胺获得药品注册证书

Core Viewpoint - Aosaikang (002755.SZ) has received approval from the National Medical Products Administration for the injection of Delafloxacin mesylate, which is considered equivalent to passing the consistency evaluation, enhancing its competitive edge in the anti-infection treatment market [1] Group 1: Product Approval - Aosaikang's wholly-owned subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd., has obtained the drug registration certificate for injectable Delafloxacin mesylate [1] - The approval will enrich the company's product portfolio in the anti-infection treatment area [1] Group 2: Market Impact - The exclusive approval for injectable Delafloxacin mesylate will create a differentiated competitive advantage in indications such as ABSSSI (Acute Bacterial Skin and Skin Structure Infections) and CABP (Community-Acquired Bacterial Pneumonia) [1] - This new treatment option will provide solutions for clinical multi-drug resistant bacterial infections, positively impacting the company's future operations [1]